Sorafenib Initiation After TACE in HCC

Описание к видео Sorafenib Initiation After TACE in HCC

Clinical perspective on transitioning to systemic therapy after chemoembolization in hepatocellular carcinoma (HCC) based on data presented by the OPTIMIS trial.

Комментарии

Информация по комментариям в разработке